Fig.1
IC50 values of cisplatin or β-Ele in OSCC cells and the enhancement of β-Ele on cisplatin sensitivity in Tca-8113-CDDP cells. a The cell viability of Tca-8113, CAL-27 and SCC-9 cells treated with different concentration of cisplatin (0–32 μg/ml) for 48 h; b the cell viability of Tca-8113 and Tca-8113-CDDP cells treated with different concentration of cisplatin (0–32 μg/ml) for 48 h; c the cell viability of Tca-8113 and Tca-8113-CDDP cells treated with different concentration of β-Ele (0–100 μg/ml) for 48 h; d the cell viability of Tca-8113-CDDP cells treated with different concentration of cisplatin (0–32 μg/ml) in the absence or presence of β-Ele (40 μg/ml) for 48 h; e the proliferation curve of Tca-8113-CDDP cells treated with β-Ele (40 μg/ml) or/and cisplatin (3.5 μg/ml); *P < 0.05, **P < 0.01, ***P < 0.001. CDDP cisplatin, β-Ele β-Elemene, OD optical density